Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, GC/MS analysis revealed variability in the quality of Syrian herbal formulations for BPH, with variations in tocopherol content, presence of parabens, and shortages of certain phytosterols.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

This review discusses how certain genetic, infectious, and metabolic conditions might influence disease severity and highlights the potential for new therapies, but it presents no new research findings.

In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review discusses the biology of antiandrogens and highlights available bioassay models to predict their therapeutic effects on human skin, reporting no new clinical results.

This study found that some cancer cells exhibit neuronal-like characteristics, which may serve as a mechanism of resistance.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

In this uncontrolled study, ivermectin treatment for scabies resulted in the resolution of symptoms and negative skin scrapings in most patients at follow-ups.

This article reviews the historical context of finasteride's development for BPH and its serendipitous discovery for hair growth, reporting no new research outcomes.

This study examined 4-azasteroids using 13C-NMR spectroscopy, detailing the NMR spectrum assignments and reporting a new molecular complex of finasteride with dioxane.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

In this study, co-administration of finasteride with oral testosterone undecanoate in young men with induced hypogonadism had no significant effect on serum testosterone or dihydrotestosterone levels, likely due to TU's unique absorption route.

Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.

In this case report, maternal use of finasteride during early pregnancy was not associated with external genitalia abnormalities in a male infant, but the findings are limited to one case and broader safety conclusions cannot be drawn.

Finasteride safely treats enlarged prostate and male-pattern baldness.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This study found that Ocimum basilicum L. showed the highest 5α-reductase inhibitory activity among ten Thai plants, despite no correlation between enzyme inhibition and total phenolic content.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Long-term use of finasteride may cause breast cancer in men.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

Finasteride and dutasteride may cause macular abnormalities.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.